S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
NYSE:ABT

Abbott Laboratories - ABT Price Target & Analyst Ratings

$111.48
+0.99 (+0.90%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$110.44
$111.53
50-Day Range
$102.07
$116.88
52-Week Range
$101.24
$142.60
Volume
2.81 million shs
Average Volume
4.21 million shs
Market Capitalization
$195.23 billion
P/E Ratio
23.27
Dividend Yield
1.69%
Price Target
$132.46

Abbott Laboratories Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 14 Analyst Ratings

Consensus Analyst Price Target

$132.46
18.82% Upside
High Prediction$150.00
Average Prediction$132.46
Low Prediction$112.00
TypeCurrent
8/14/21 to 8/14/22
1 Month Ago
7/15/21 to 7/15/22
3 Months Ago
5/16/21 to 5/16/22
1 Year Ago
8/14/20 to 8/14/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
13 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$132.46$136.73$140.66$124.67
Predicted Upside18.82% Upside16.04% Upside16.60% Upside10.90% Upside
Get Abbott Laboratories Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.


ABT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Abbott Laboratories Stock vs. The Competition

TypeAbbott LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.71
2.50
Consensus RatingModerate BuyBuyHold
Predicted Upside18.82% Upside722.51% Upside13.84% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
887
70.73%
Underperform Votes
367
29.27%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/27/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$142.00 ➝ $128.00+17.45%
7/22/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$112.00+2.56%
7/21/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$134.00 ➝ $132.00+21.96%
7/21/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$143.00 ➝ $132.00+21.96%
7/21/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$125.00 ➝ $123.00+13.65%
7/18/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$130.00 ➝ $126.00+15.79%
7/18/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$136.00 ➝ $126.00+15.79%
7/13/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$150.00 ➝ $130.00+22.02%
7/5/2022Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderperform
4/21/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$143.00 ➝ $135.00+10.08%
4/8/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$155.00 ➝ $150.00+21.59%
3/1/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy ➝ Buy$140.00+18.47%
1/27/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$138.00 ➝ $139.00+15.77%
10/27/2021Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$144.00+12.39%
10/21/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform$128.00 ➝ $140.00+13.53%
10/14/2021Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Simon Baker
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$103.13 ➝ $132.28+13.06%
6/2/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$150.00 ➝ $125.00+18.16%
4/20/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kaczor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
10/22/2020Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$113.00 ➝ $123.00+16.11%
10/9/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$110.00 ➝ $125.00+15.16%
9/2/2020The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Amit Hazan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetSell$94.00-11.78%
7/23/2020Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$110.00 ➝ $125.00+24.06%
4/16/2020Cfra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$99.00 ➝ $101.00+5.64%
1/2/2020Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
(Data available from 8/14/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ABT Price Target - Frequently Asked Questions

What is Abbott Laboratories's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Abbott Laboratories stock is Moderate Buy based on the current 1 sell rating, 2 hold ratings and 11 buy ratings for ABT. The average twelve-month price prediction for Abbott Laboratories is $132.46 with a high price target of $150.00 and a low price target of $112.00. Learn more on ABT's analyst rating history.

Do Wall Street analysts like Abbott Laboratories more than its competitors?

Analysts like Abbott Laboratories more than other Medical companies. The consensus rating for Abbott Laboratories is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ABT compares to other companies.

Do MarketBeat users like Abbott Laboratories more than its competitors?

MarketBeat users like Abbott Laboratories more than other Medical companies. 70.73% of MarketBeat users gave Abbott Laboratories an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Does Abbott Laboratories's stock price have much upside?

According to analysts, Abbott Laboratories's stock has a predicted upside of 14.46% based on their 12-month price targets.

What analysts cover Abbott Laboratories?

Abbott Laboratories has been rated by BTIG Research, Citigroup, Cowen, Cowen, Evercore ISI, Morgan Stanley, Royal Bank of Canada, Stifel Nicolaus, UBS Group, and Wolfe Research in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:ABT) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.